Related Experiment Videos
Does HIV test result influence methadone maintenance treatment retention?
J Wimbush1, A Amicarelli, M D Stein
1Department of Medicine, Brown University, USA.
Journal of Substance Abuse
|January 1, 1996
Summary
HIV status does not impact methadone treatment dropout rates for new opioid users. Voluntary HIV testing can be safely integrated into drug treatment programs for AIDS prevention without negatively affecting patient outcomes.
Area of Science:
- Addiction Medicine
- Infectious Disease Prevention
- Public Health
Background:
- Opioid users in treatment are at risk for HIV.
- Understanding factors influencing treatment retention is crucial for effective addiction management and public health interventions.
Purpose of the Study:
- To investigate whether learning of HIV-seropositivity impacts treatment dropout among new opioid users in methadone maintenance.
- To assess the feasibility of integrating voluntary HIV testing into drug treatment programs.
Main Methods:
- Compared treatment continuation rates at 6 and 12 weeks between HIV-seropositive and HIV-seronegative opioid users starting methadone maintenance.
- HIV status was determined upon entry into the drug treatment program.
Main Results:
- No significant difference in methadone treatment continuation was observed between patients who learned they were HIV-seropositive and those who learned they were seronegative.
- Treatment retention was not adversely affected by HIV serostatus.
Conclusions:
- HIV serostatus is not a predictor of dropout in new methadone maintenance patients.
- Voluntary HIV testing can be implemented within drug treatment settings as part of AIDS prevention strategies without compromising treatment outcomes.